Sibutramine‐associated adverse effects: a practical guide for its safe use
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Summary: Obesity is a multifactorial chronic disorder which comprises a serious health problem nowadays. The effective management of obesity is difficult in contemporary societies where abundance of hypercaloric food and sedentary lifestyle is the rule. Apart from lifestyle interventions, which include diet, exercise and behavioural treatment, weight‐loss medications can also be used for the management of obesity. Sibutramine, a selective monoamine reuptake inhibitor, is a drug with established efficacy in sustained weight reduction and an overall favourable safety profile. However, its action on the sympathetic nervous system has linked sibutramine to blood pressure and heart rate elevations. These potentially adverse effects as well as other sibutramine‐associated side effects and their possible underlying mechanisms are reviewed in the present article. Compelling evidence from the majority of data in the literature shows that sibutramine can be effectively used in conjunction with caloric restriction and exercise in obese patients. Hypertension, if adequately treated and frequently monitored, is not an absolute contraindication for the prescription of sibutramine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · cited 3×
“Common side effects include insomnia, dry mouth, constipation, nausea and headache (12,39).”
Sympathetic Activation in Obese Normotensive Subjects
Grassi, G., Seravalle, G., Cattaneo, B. M., Bolla, G. B., Lanfranchi, A., Colombo, M., Giannattasio, C., Brunani, A., Cavagnini, F., & Mancia, G. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.560 · Cited by 614 · cited 1×
“When sympathetic nerve activity is increased, as is the case with hypertensive patients (70), the inhibitory clonidine-like effects of sibutramine might predominate.”
Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
Alwan, S., Reefhuis, J., Rasmussen, S. A., Olney, R. S., & Friedman, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066584 · Cited by 495 · cited 1×
“However, two large studies examining the teratogenic potential of SSRIs suggest that any SSRI-related increased risk of congenital malformations is likely to be small in terms of absolute risks (94,95).”
Role of serotonin in memory impairment.
Buhot, M.-C., Martin, S., & Segu, L. (2000) · Annals of Medicine · doi:10.3109/07853890008998828 · Cited by 419
Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00081.x · Cited by 244 · cited 1×
“In some studies, BP increases were reported following sibutramine administration, both in patients with (28,52) and without (28,53) pre-existing hypertension.”
Cited by
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Dietary supplements as source of unintentional doping
Kozhuharov, V. R., Ivanov, K., & Ivanova, S. (2022) · BioMed Research International · doi:10.1155/2022/8387271 · Cited by 108
“Consumers who have unintended intake of sibutramine because of a contaminated dietary supplement may feel increases in the blood pressure, arrhythmias, or other side e ff ects like dry mouth, trouble sleeping, headache, fl ushing, or joint/muscle pain [117, 118, 120, 121].”
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity
Paspala, I., Katsiki, N., Kapoukranidou, D., Mikhailidis, D. P., & Tsiligiroglou-Fachantidou, A. (2012) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401206010147 · Cited by 18
Metadata
- Authors
- Florentin, M., Liberopoulos, E. N., & Elisaf, M. S.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2007-11-23
- Volume
- 9
- Issue
- 4
- Pages
- 378-387
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2109511007
- Cited by
- 78
- References
- 17
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sibutramine‐associated adverse effects: a practical guide for its safe use. https://app.cochat.ai/papers/10.1111/j.1467-789x.2007.00425.x
- The paper
- Florentin, M., Liberopoulos, E. N., & Elisaf, M. S. (2008). Sibutramine‐associated adverse effects: a practical guide for its safe use. Obesity Reviews. https://doi.org/10.1111/j.1467-789x.2007.00425.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.